Drug-induced hyperprolactinaemia: A case/non-case study in the French pharmacovigilance database;Hyperprolactinémies d'origine médicamenteuse: Étude cas/non-cas dans la banque nationale de pharmacovigilance

Therapie

Volumn 58, Issue 2, 2003, Pages 159-163

  Petit, Abir ^a,b   Piednoir, Dorothée ^a   Germain, Marie Laure ^a   Trenque, Thierry ^a  

^a REIMS UNIVERSITY HOSPITAL   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Adverse effects; Drug risk factor; Hyperprolactinaemia; Pharmacovigilance

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CHORIONIC GONADOTROPIN BETA SUBUNIT; CIMETIDINE; CITALOPRAM; ESTRADIOL; FLUNARIZINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HALOPERIDOL; HISTAMINE H2 RECEPTOR ANTAGONIST; INDORAMIN; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PAROXETINE; PROLACTIN; RANITIDINE; RISPERIDONE; SERTRALINE; VERALIPRIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL PRACTICE; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; SEX RATIO;

EID: 0042656400     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2003023     Document Type: Article

References (13)

1. Conner P, Fried G. Hyperprolactinemia: etiology, diagnosis, and treatment alternatives. Acta Obstet Gynecol Scand 1998; 77: 249-62
2. Biller BM, Luciano A, Crosignani PG, et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 1999; 44: 1075-84
3. Fauci AS, Braunwald E, Isselbacher KJ, et al. Régulation neuroendocrinienne et pathologie antéhypophysaire et hypothalamique. In: Harrison Medecine Interne. 14° éd. McGraw-Hill: New-York, 1998: 2271-6
4. Chanson P, Young J. Hyperprolactinémie. In: Endocrinologie. Paris: Doin éditeurs, 2000: 359-65
5. Hennekens CH, Buring JE, Mayrent SL. Mesures de la fréquence de la maladie. In: Epidémiologie en médecine. Paris: Frison-Roche, 1998: 52-96
6. Morabia A. Traitement. In: L'épidémiologie clinique. París: Presses Universitaires de France, 1996: 48-72
7. Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case in the French pharmacovigilance system database. Br J Clin Pharmacol 1998; 44: 513-8
8. Vincens M. Hyperprolactinémies iatrogènes. Rev Prat 1981; 31: 299-302
9. Pradalier A, Vincent D, Barzegar C. Hyperprolactinémie induite par l'indoramine. Thérapie 1998; 53: 500-2
10. Brient-Clabaux J. Agréal: acceptabilité. Revue de la littérature. Rev Fr Gynécol Obstet 1985; 80: 167-70
11. Berra F, Jonville-Bare AP, Doustin P, et al. Impuissance et gynécomastie secondaires à une hyperprolactinémie par la ranitidine. Thérapie 1994; 49: 361-2
12. Davies PH. Drug-related hyperprolactinemia. Adverse Drug React Toxicol Rev 1997; 16: 83-94
13. Ehrinpreis MN, Dhar R, Narula A. Cimetidine-induced galactorrhea. Am J Gastroenterol 1989; 84: 563-5